The Food and Drug Administration first approved Vyvanse as a once-a-day pill for attention deficit hyperactivity disorder in 2007. On Friday the agency cleared the drug for adults who compulsively overeat. Side effects of the drug, made by Shire PLC, can include psychiatric problems like hallucinations and mania as well as heart complications.» Read More
Art Levinson and Miles White are "Kings of the Jungle." At least Barron's thinks they are. The weekly investment periodical picked the pair as the only two from biopharma to make its annual list of the "30 Most Respected CEOs."
My first week on Twitter has gone pretty well. Despite some Twitter trouble (or should that be twubble?) with website capacity, I've picked up more than 75 followers already.
Normally, the folks at GlaxoSmithKline keep us tightly in the loop when there's news. So, I'm a bit surprised that it took a "tweet" on Twitter this morning to learn that four days ago the company put out a press release that has "Pharma's Market" written all over it.
Pfizer announced this morning that it's raising the income levels for uninsured people to qualify for cheaper or free drugs because of the bad economy.
Scientific and medical journals like to keep their distance from the business side of things. That's why I think it's worth noting that a "Perspective" piece--think of it as kind of a newspaper Op-Ed--in "The New England Journal of Medicine" starts by mentioning Pfizer's stock price and its recent proposed acquisition of Wyeth.
Despite my repeated invitations for his first post-jailhouse interview on this blog and through one of his contacts, Sam Waksal didn't respond. Given his Manhattan social scene background it should not, perhaps, come as a surprise that the founder of ImClone Systems decided to have his coming-out party in "New York" magazine.
The overwhelming majority of people who have voted in the “Pharma’s Market” poll about the future of Genentech’s execs and top scientists thinks most of them will eventually bolt.
Last week was a busy week, to say the least, on the Pharma beat - So I was looking forward to the weekend and escaping all things drug-related. But as fate would have it, it ended up being bookended by references to pharma in a couple of surprising venues.
All of a sudden yesterday and today shares of Dendreon —my favorite biotech story—shot up on heavy volume.
Shares of Dow component Merck rare getting a nice little shot in the arm this morning on an upgrade by Dr. Tim Anderson at Sanford C. Bernstein. He's putting an "Outperform" or "Buy" rating on MRK and raising his target price three bucks to $30.
Only on a day like today when it's wall-to-wall Madoff coverage would a $47 billion deal, the second $40-billion-plus deal to be done in four days, struggle to get some airtime.
When a press release crosses the wires or pops into the inbox from a Dow component announcing positive late-stage test results on a cancer drug, you rush to get the headlines on the air as quickly as possible.
The Biotechnology Industry Organization just announced that Sir Elton will be the keynote speaker at the 2009 BIO International Convention in Atlanta, the superstar's American hometown.
On my Thomson Reuters screen I have the stock quotes of a few dozen of the biopharma companies I cover. Lately, when I glance over at it, there's been a lot of red. With today's market rally, there's a whole lotta green. And that's why the quote in red for Genentech kind of sticks out like a sore thumb.
They may have the same name, but America's oldest teenager Dick Clark and Merck's Chairman and CEO Dick Clark appear to have little else in common. One loves the camera, the other not so much.
New Jersey, where I live and work, is known as "The World's Medicine Chest" or "The Silicon Valley of Pharma."
Yeah, "Deal Or No Deal" has become a bit of a tired cliche, but I think it's totally appropriate in the context of the latest salvo in the Roche-Genentech takeover battle.
Japan and Januvia. No, it's not a country—not even a fictional one—even though it sounds like "Genovia" in "The Princess Diaries." It's a diabetes drug from Merck.
As Pfizer Chairman and CEO Jeff Kindler represents at the White House Healthcare Summit today and tries to make the industry's case against government price controls on prescription drugs, a couple of prominent industry analysts are giving him a little something to smile about.
Forget about mergers and acquisitions (M & A). Think about partnerships and acquisitions or what Leerink Swann, which specializes in healthcare stock coverage, is calling "P & A."